Non-alcoholic fatty liver disease is currently the most common chronic liver disease, affecting up to 25% of the global population. Simple fatty liver, in which fat is deposited in the liver without fibrosis, has been regarded as a benign disease in the past, but it is now known to be prognostic. In the future, more emphasis should be placed on the quantification of liver fat. Traditionally, fatty liver has been assessed by histological evaluation, which requires an invasive examination; however, technological innovations have made it possible to evaluate fatty liver by non-invasive imaging methods, such as ultrasonography, computed tomography, and magnetic resonance imaging. In addition, quantitative as well as qualitative measurements for the detection of fatty liver have become available. In this review, we summarize the currently used qualitative evaluations of fatty liver and discuss quantitative evaluations that are expected to further develop in the future.
Citations
Citations to this article as recorded by
Evaluation of thyroid function in patients diagnosed with metabolic dysfunction-associated fatty liver disease: a cross-sectional study Ahmed M. Eldaba, Mona M. Watany, Galal El Din M. Elkassas, Rehab B. El sheshtawy Tanta Medical Journal.2026; 54(1): 143. CrossRef
Circulating hepatocyte-derived extracellular particles as potential biomarker of steatohepatitis progression to fibrogenesis: Exploring the impact of smoking Oumnia Masrour, Justine Morvan, Alison Rapin, Alexis Aimé, Agnès Burel, Valentine Genêt, Stéphanie Brisset, Dominique Lagadic-Gossmann, Edouard Bardou-Jacquet, Corinne Martin-Chouly Digestive and Liver Disease.2026;[Epub] CrossRef
Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals Giovani Schulte Farina, Bárbara Brambilla, Emanuelle Mendonça Pandolfo, Laura Kalil Nader Lazzaretti, Stéfano Mateus Schio Kuiava, Ana Maria Graciolli, Vitória Maria Kriger, Carlos Henrique Dal Bem Fistarol, Augusto Cardoso Sgarioni, Henrique Prataviera G World Journal of Hepatology.2026;[Epub] CrossRef
Thyroid Stimulating Hormone Levels Are Related to Fatty Liver Indices Independently of Free Thyroxine: A Cross-Sectional Study Federica Sileo, Alessandro Leone, Ramona De Amicis, Andrea Foppiani, Laila Vignati, Francesca Menichetti, Giorgia Pozzi, Simona Bertoli, Alberto Battezzati Journal of Clinical Medicine.2025; 14(7): 2401. CrossRef
The application performance of MRI-PDFF detection values of different hepatic lobes in diagnosing liver steatosis Fengjie Qiao, Yan Xue, Chen Zou, Kun Liu, Jie Yuan, Longshan Ji, Lingying Huang, Man Li, Yueqiu Gao Clinical and Experimental Medicine.2025;[Epub] CrossRef
The value of ultrasonic attenuation parameters and serum indicators on MASLD patients with liver fat degenerationality Yan Liu, Wen Kang, Jingya Su, Yin Yang, Kui Li, Juntao Yang Journal of Radiation Research and Applied Sciences.2025; 18(3): 101647. CrossRef
Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis Toshikazu Kohira, Satoshi Oeda, Erina Eto, Yoshihito Kubotsu, Misa Norita, Kaori Inoue, Nagisa Hara, Shotaro Noge, Kenichi Tanaka, Shigenobu Yoshimura, Noriko Oza, Keizo Anzai, Yuichiro Eguchi, Cheng Han Ng, Daniel Q. Huang, Mark D. Muthiah, Atsushi Kawag Scientific Reports.2025;[Epub] CrossRef
Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li European Journal of Medical Research.2025;[Epub] CrossRef
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in
Patients with Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review
and Meta-Analysis of Randomized Controlled Trials Simei Huang, Yu Xi, Yanqing Hong, Chenliang Hu Hormone and Metabolic Research.2025; 57(10): 593. CrossRef
Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction–associated Steatotic Liver Disease: Radiologists’ Perspective Eri G. Osta, Florentino Saenz Rios, Sriram Jaganathan, Courtney Thomas, Eugenia Tsai, Venkateswar Surabhi, Srinivasa R. Prasad, Venkata S. Katabathina RadioGraphics.2025;[Epub] CrossRef
3D multiparametric ultrasound imaging of steatotic liver disease in a study with male rats Donghyun Lee, Jinseok Heo, Hyeonji Mun, Donghyeon Oh, Yongjoo Ahn, Chulhong Kim Nature Communications.2025;[Epub] CrossRef
Near-Infrared Fluorescent Lipid Droplet Polarity Probe for Distinguishing Different Liver Injury Diseases Xiaodong Tan, Yijia Liu, Siyu Jiang, Zhoupeng Zheng, Guoqiang Feng Chemical & Biomedical Imaging.2025;[Epub] CrossRef
Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374. CrossRef
Utilizing fully-automated 3D organ segmentation for hepatic steatosis assessment with CT attenuation-based parameters Jeongin Yoo, Ijin Joo, Sun Kyung Jeon, Junghoan Park, Soon Ho Yoon European Radiology.2024; 34(9): 6205. CrossRef
Non–small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect? Yi Li, Bingxin Gong, Yusheng Guo, Weiwei Liu, Chao Chen, Shanshan Jiang, Feng Pan, Jiyu Song, Lian Yang, Guofeng Zhou BMC Cancer.2024;[Epub] CrossRef
Head-to-head comparison of three different US-based quantitative parameters for hepatic steatosis assessment: a prospective study Yan Zhou, Mengjin Nie, Hongyu Zhou, Feng Mao, Lin Zhao, Jianmin Ding, Xiang Jing Abdominal Radiology.2024; 49(7): 2262. CrossRef
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD Farah Abdelhameed, Chris Kite, Lukasz Lagojda, Alexander Dallaway, Kamaljit Kaur Chatha, Surinderjeet S. Chaggar, Maria Dalamaga, Eva Kassi, Ioannis Kyrou, Harpal S. Randeva Current Obesity Reports.2024; 13(3): 510. CrossRef
Maternal obesity and metabolic (dysfunction) associated fatty liver disease in pregnancy: a comprehensive narrative review Bianca M. Leca, Lukasz Lagojda, Chris Kite, Emmanouil Karteris, Eva Kassi, Harpal S. Randeva, Ioannis Kyrou Expert Review of Endocrinology & Metabolism.2024; 19(4): 335. CrossRef
Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity Wah‐Kheong Chan, Salvatore Petta, Mazen Noureddin, George Boon Bee Goh, Vincent Wai‐Sun Wong Alimentary Pharmacology & Therapeutics.2024;[Epub] CrossRef
This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol Anja M. Fischer, Nazim Lechea, Harvey O. Coxson Seminars in Liver Disease.2024; 44(02): 226. CrossRef
Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis” Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim Clinical and Molecular Hepatology.2024; 30(4): 989. CrossRef
From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions Bruno Basil, Blessing K. Myke-Mbata, Onyinye E. Eze, Augustine U. Akubue Clinical Diabetes and Endocrinology.2024;[Epub] CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Lynna Alnimer, Mazen Noureddin Clinical and Molecular Hepatology.2023; 29(2): 394. CrossRef
Application of attenuation imaging for the detection of fatty liver in potential liver donors Jae Seok Bae, Dong Ho Lee, Kyung-Suk Suh, Kwang-Woong Lee, Nam-Joon Yi, Suk Kyun Hong European Journal of Radiology.2023; 166: 110958. CrossRef
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD? Angeliki Pappa, Tobias Wenzl Alimentary Pharmacology & Therapeutics.2023; 58(3): 364. CrossRef
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis Martina Maurelli, Paolo Gisondi, Francesco Bellinato, Alessandro Mantovani, Giovanni Targher, Giampiero Girolomoni Journal of Clinical Medicine.2023; 12(18): 6057. CrossRef
First
Prev
